Recruitment to Kyntheum (brodalumab), Cimzia (certolizumab pegol), and Skilarence (dimethyl fumarate) has now ended. Patients who were consented and started these treatments before the 1^st August must be added to the database before 21^st August. Recruitment is temporarily paused on Ilumetri (tildrakizumab) from 1^st August and we will provide an update as soon as possible.

BADBIR is now open to registrations of patients commencing on the small molecule drug Sotyktu (deucravacitinib). Patients can be recruited even if they’re biologic-exposed.

Please see the eligibility page for full details of the treatments we currently recruit for.

Related